Press Release: "phaware global association® and Antidote Technologies Collaborate on Unique Patient Engagement Model to Accelerate Lung Disease Research"
Partnership provides CROs and pharmaceutical companies end-to-end clinical trial recruitment services through an extensive network of patients with chronic lung diseases
New York, NY and Burbank, CA (August 23, 2018) — Antidote, a digital health company that forges strategic partnerships across the clinical development ecosystem, and phaware®, an advocacy organization dedicated to creating global pulmonary hypertension (PH) awareness, today announced a strategic partnership that will provide comprehensive patient recruitment services to pharmaceutical companies and CROs running trials in chronic lung diseases.
This new alliance combines phaware’s robust patient engagement model with Antidote’s proven end-to-end clinical trial recruitment methods to accelerate medical research for PH and related diseases by driving recruitment efficiencies in these rare conditions. The joint services of Antidote and phaware® provide researchers with:
- Unique access to patients affected by PH and related diseases through phaware’s engaged community of patients and caregivers
- Highly efficient screening technology via Antidote’s customized pre-screeners, advanced eligibility matching technology, and phone validation service
- Effective referral management services to enrollment through Antidote’s site coordination services
- Insights for feasibility and recruitment planning based on Antidote’s fully transparent enrollment analytics
The acceleration of research in PH is critical. While research has brought 14 treatments to market since 1995, there is only one treatment approved for children. Pulmonary hypertension is a rare, life-threatening disease affecting the arteries of the lungs that can lead to right heart failure. Having lost her daughter, Chloë, to PH, Marie Rand, Co-Founder and Managing Director of phaware®, knows the importance of participating in research all too well. Before she passed away, Marie’s daughter was a major part of a pioneering PH clinical trial for a drug that was approved in 1995. “We need to get patients into trials today to improve their lives, as well as the lives of patients in the future,” said Rand. “We’re excited to partner with Antidote to bring our patients through the enrollment funnel so that they can contribute to innovations that will someday change the face of PH.”
This partnership comes at a time when there are more than 90+ PH trials currently enrolling patients in the United states, which need more than 21,000 patients to take part. With 30,000 patients diagnosed with PH in the US, that means that 70% of patients need to participate to maximize research acceleration. This inherent challenge of recruiting patients for rare disease clinical trials can be frustrating for researchers, who want to stay on time and on budget, as well as for patients, who are eager for new and better treatments. More efficient recruitment is a key solution to this issue.
“At Antidote, our mission is to connect patients to research through partnerships like the one we have forged with phaware®,” said Tom Krohn, Chief Development Officer at Antidote. “The community that phaware® has built is inspiring, and we are honored to help these patients take part in potential breakthrough research opportunities.”
In the United States today, nearly 80% of clinical trials are delayed or closed due to difficulty finding the right patients to take part, and these delays can cost researchers up to $8M per day. It’s time to explore new models to help willing and interested patients join clinical trials. For more information, please visit www.phaware.global/clinicaltrials or www.antidote.me.
phaware global association® is a 501(c)3 organization dedicated to raising global awareness and creating innovative technology for research. phaware® was co-founded by pulmonary hypertension community members who together bring unique for-profit expertise to the nonprofit world. The organization’s goal is to use technology to create a global footprint and address PH patients’ needs around the world. For more information, please visit www.phaware.global.
Antidote is a digital health company on a mission to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need it. In a world where 80% of clinical trials are delayed or closed due to lack of participants , Antidote uses cutting-edge technology to match the right patients with the right trials, helping medical researchers make faster progress, and offering new treatment options to patients. Antidote MatchTM, the company’s unique trial matching tool, currently powers clinical trial search for more than 250 patient communities and health portals — bringing clinical trial awareness, matching, and access to more than 15 million patients a month. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit www.antidote.me.
Director of Communications, Antidote
VP of Partnerships and Communications, Antidote
Co-Founder and Managing Director, phaware global association®
- What is PH? Retrieved from http://www.phaware.global/facts/.
- PH is Rare. Retrieved from http://www.phaware.global/rare/.
- Garrun, Daniel. (2012, July 18). Clinical trial delays: America’s patient recruitment dilemma. Retrieved from https://www.drugdevelopment-technology.com/features/featureclinical-trial-patient-recruitment/.